A number of biologics targeting ILC pathways, such as dupilumab (anti IL-4/IL-13 receptor), etokimab (anti-IL-33) and tepezulmab (anti-TSLP) have been trialled in food allergy and other atopic diseases [54▪,58,59]. The gene discussed is IL4; the disease is food allergy.